Boehringer Ingelheim International Gmbh

Sprout Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Fabio Paleari

Klaus Rudolf

Henri Doods

Dirk Stenkamp

Philipp Lustenberger

Stephan Georg Mueller

Marco Santagostino

Gerhard Schaenzle

Kirsten Arndt

Alexander Dreyer

Ralf Lotz

Astrid Volz

Rudlof Klaus

The present invention pertains to a compound of formula (I) wherein R, R, R, and Rare each hydrogen or sulfate monoester with the proviso that R, R, R, and Rcannot simultaneously be hydrogen, processess for their preparation and their use as pharmaceuticals in the treatment of CNS disorders.

Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claimthe tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP-antagonists of general formula I wherein R, R, Rand Rare defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Selected CGRP-antagonists, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claim,the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

The present invention relates to the CGRP-antagonists of general formula I wherein R, R, R, Rand X are defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I in which one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.

CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, Q and Rto Rare defined as in claim, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claim 1,

The present invention relates to the CGRP-antagonists of general formula I wherein R, R, Rand Rare defined as in claimthe tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, as well as those compounds of general formula I wherein one or more hydrogen atoms are replaced by deuterium, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and Rto Rare defined as in claim,

Growing community of inventors

Monza, Italy

Fabio Paleari